ARTICLE | Strategy
Grow your own way
How Bayer plans to access and grow new tech, starting with CRISPR deal
January 4, 2016 8:00 AM UTC
Bayer AG's joint venture with CRISPR Therapeutics AG is the first for the pharma's new life sciences center, which intends to back nascent technologies with resources to solve platform-wide challenges and then deploy the technologies broadly.
Bayer formed the Bayer LifeScience Center (BLSC) about a year ago to develop platform technologies with curative potential. The center has selected five focus areas: gene editing with CRISPR, RNA inhibition, RNA activation, microbial-based therapies and cell or regenerative therapies...